Today there are many types of therapies (medical and surgical) in BPH treatment. The Authors suggest dividing BPH into two components: a dynamic phase and a static phase. On the basis of this, they used an association of finasteride and alfuzosin in short and long-term therapy. Provided the rationale is correct, the results in terms of improved flow and symptomatology score suggest that this is an optimal solution.
GormleyG.J., StonerE., BruskewitzR.C., ImperatoJ., GinleyMc., WalshP.C., Mc. ConnellJ.D., AndrioleG.L., GellerJ., BrackenB.R., TenoverJ.S., VaughanE.D., PappasF., TaylorA., BinkowitzB. and NG J. for the finasteride story group: The effects of finasteride in men with benign prostatic hyperplasia. New Eng. J. Med., 327: 1185–1191, 1992.
2.
LeporH., AverbachS., Puras BaezA., NarayanP., SolowayM., LoweF., MoonT., LeiferG., Madsenand: A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol., 148: 1467, 1992.
3.
JardinA.: Efficacy of alfuzosin, an alpha-blocker, on micturition disorder in men with prostatic adenoma. Results of a European multicentre trial. Prostata et alpha-bloquans, Amsterdam. Excerpta Medica, 391–402, 1989.
